ClinOleic

Per 1,000 mL Refined olive oil + refined soy bean oil 200 g (80% olive oil + 20% soybean oil). Energy: 2,000 kCal

Source of lipids for patients requiring parenteral nutrition when oral or enteral nutrition is impossible, insufficient or contraindicated.

Adult 1 g/kg daily up to max of 2 g lipids/kg daily by slow infusion rate, & not to exceed 0.1 g lipids or 0.5 mL (10 drops) per min for 10 min, then gradually increased until required rate is reached after ½ hr. Max: Not to exceed 0.15 g lipids/kg/hr (0.75 mL/kg/hr). Adult weighing 70 kg 70-140 g lipids (350-700 mL) daily. Childn Administer as continuous infusion 24 hr daily gradually increased daily dose during 1st wk of administration. Max daily dose: Not to exceed 3 g lipids/kg. Max infusion rate: 0.15 g lipids/kg/hr. Premature newborn & low birth wt infants ≥28 wk Administer as continuous infusion 24 hr daily. Initially 0.5-1 g lipids/kg daily, may be increased by 0.5-1 g lipids/kg every 24 hr up to 2 g lipids/kg daily.

Known hypersensitivity to olive & soybean oil or egg or soybean protein. Severe hyperlipidemia or lipid metabolism disorders characterized by hypertriglyceridemia; non-corrected metabolism disorders including lactic acidosis & uncompensated diabetes; severe sepsis; blood coagulation disorders, thrombophlebitis; MI. Severe liver disease.

Not to connect bags in series to avoid air embolism. Discontinue immediately if any signs or symptoms of allergic reaction develop. Predisposed to infectious complications due to malnutrition &/or their underlying disease state. Infection & sepsis; fat overload & re-feeding syndrome; thiamine deficiency & fluid retention. Slowly increase nutrient intakes & avoid overfeeding. Patient w/ acute oliguria or anuria; pulmonary edema or heart failure. Fever, chills, leukocytosis & hyperglycemia. Avoid light exposure after admixture. Monitor serum triglycerides, fluid & electrolyte status, serum osmolarity, blood glucose, liver & kidney function, blood count, including platelets & coagulation parameters throughout treatment. Correct severe fluid overload states, water/electrolyte & metabolic disorders prior to infusion. Regularly check alkaline phosphatases & total bilirubin during short- & long-term IV nutrition; blood sugar, acid-base balance, electrolytes, & blood count. Preexisting liver disease or insufficiency. Cholestasis, hepatic steatosis, fibrosis & cirrhosis, possibly leading to hepatic failure, cholecystitis & cholelithiasis. Pregnancy & lactation. Premature infants ≥28 wk gestational age. Neonatal hyperbilirubinemia. Neonates & childn <2 yr.

Leukopenia; hyperglycemia, hypoproteinaemia, hyperlipidemia; decreased mean arterial pressure, circulatory collapse, hypotension, hot flush; dyspnea; vomiting/nausea, abdominal pain & distension, epigastric discomfort; cholestasis, cytolytic hepatitis; muscle spasms, back pain; pyrexia, asthenia, malaise; increased blood bilirubin, pancreatic enzyme & blood triglycerides, abnormal LFT. Diarrhea; pruritus; hypersensitivity w/ manifestations of rash & dyspnea; decreased INR. Thrombocytopenia; parenteral nutrition associated liver disease including hepatic failure, cirrhosis, fibrosis & steatosis, cholestasis, cholecystitis, cholelithiasis; fat overload syndrome.

Counteracts anticoagulant activity of coumarin derivatives, including warfarin. Interference w/ results of certain lab tests if blood sample is taken prior to lipid elimination.

Parenteral Nutritional Products

B05BA02 - fat emulsions ; Belongs to the class of solutions for parenteral nutrition used in I.V. solutions.

D